E
EXOZYMES INC.
EXOZCIK 0002010788NasdaqEmerging GrowthBiological Products, (No Diagnostic Substances)NevadaFY ends Dec 31
Period
FY 2025
Revenue
—
Net Income
$-9.16M
Total Assets
$5.97M
Equity
$3.40M
Shares Out
8.48M
Op. Cash Flow
$-6.50M
Business
eXoZymes Inc. is a development-stage biomanufacturing company that engineers cell-free enzyme systems (exozymes) to produce valuable chemicals including active pharmaceutical ingredients, nutraceuticals, and biofuels. The company develops proprietary enzyme catalysts and biosolutions using artificial intelligence and bioengineering to convert feedstocks into target compounds in bioreactors without living cells. eXoZymes operates through a platform-based business model focused initially on nutraceutical-with-pharmaceutical-potential applications, with commercialization planned via spinouts, joint ventures, and licensing partnerships; it is currently advancing N-trans-caffeoyltyramine (NCT) as a lead candidate and isobutanol production for sustainable aviation fuel.
Summary from 10-K filed 2026-03-30
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 |
|---|---|---|---|---|
| Total operating income | — | — | 70,069 | |
| Compensation | 4 | 3 | 596,174 | |
| Professional fees | 1 | 1 | 436,338 | |
| Information technology | 95,989 | 38,658 | 21,803 | |
| General and administrative-other | 836,076 | 329,660 | 284,496 | |
| Total general and administrative costs | 6 | 4 | 1 | |
| Research and development costs | 4 | 2 | 527,480 | |
| Total operating costs | 10 | 6 | 2 | |
| Net operating loss | −10 | −6 | −2 | |
| Interest income, net | 363,786 | 77,612 | 100 | |
| Other income/(expense) | 88,746 | −6,834 | — | |
| Change in fair value of SAFE | — | −8 | −200,000 | |
| Loss before income taxes | −9 | −6 | −2 | |
| Income tax benefit | 105,205 | — | −42,267 | |
| Net loss | −9 | −6 | −2 | |
| Net loss per common share - basic | −1.09 | −0.89 | −0.33 | |
| Net loss per common share - diluted | −1.09 | −0.89 | −0.33 | |
| Weighted average of common shares outstanding - basic | 8 | 7 | 6 | |
| Weighted average of common shares outstanding - diluted | 8 | 7 | 6 |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|
| Cash and cash equivalents | 3 | 10 | 66,533 | — | |
| Grants receivable | 517,359 | 737,282 | 882,319 | 809,532 | |
| Prepaid expenses and other current assets | 382,886 | 363,790 | 264,762 | — | |
| Total current assets | 4 | 11 | 1 | — | |
| Property and equipment, net | 764,401 | 882,445 | 753,376 | — | |
| Operating lease right-of-use asset, net | 1 | 1 | 2 | — | |
| Finance lease right-of-use asset, net | 108,682 | — | — | — | |
| Tax receivable | 105,205 | — | — | — | |
| Total assets | 6 | 13 | 4 | — | |
| Accounts payable | 1 | 924,252 | 702,911 | — | |
| Due to affiliates | 5,330 | 178,966 | 445,128 | — | |
| Operating lease liabilities Current | 281,979 | 230,027 | 224,988 | — | |
| Finance lease liabilities Current | 44,255 | — | — | — | |
| Total current Liabilities | 2 | 1 | 2 | — | |
| Deferred grant reimbursement | 90,365 | 123,579 | 140,703 | — | |
| Operating lease liabilities - Long term | 852,575 | 1 | 1 | — | |
| Finance lease liabilities - Long term | 64,427 | — | — | — | |
| Total liabilities | 3 | 3 | 4 | — | |
| Preferred stock, $0.000001 par value, 5,000,000 shares authorized; no shares issued and outstanding on December 31, 2025, and December 31, 2024, respectively. | — | — | — | — | |
| Common shares, 100,000,000 authorized shares at $0.000001; 8,406,681 and 8,367,810 shares issued and outstanding as of December 31, 2025, and December 31, 2024, respectively | 8 | 8 | 6 | — | |
| Additional Paid-in-capital | 25 | 22 | 6 | — | |
| Accumulated (deficit) | −21 | −12 | −6 | — | |
| Total stockholders equity | 3 | 10 | −384,319 | 1 | |
| Total liabilities and stockholders equity (deficit) | 6 | 13 | 4 | — |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 |
|---|---|---|---|---|
| Amortization of Deferred Grant Reimbursement | −52,913 | −54,359 | −51,840 | |
| Depreciation of property and equipment | 287,961 | 267,382 | 196,937 | |
| Non-cash lease expense | 53,367 | 34,955 | 10,570 | |
| Stock-based compensation | 2 | 1 | 281,538 | |
| Change in fair value of SAFE | — | 8 | 200,000 | |
| Grants receivable | 219,923 | 145,037 | −72,787 | |
| Prepaid expenses and other current assets | −19,096 | −99,028 | −163,625 | |
| Tax receivable | −105,205 | — | — | |
| Accounts payable and accrued expenses | 311,085 | 221,340 | 272,890 | |
| Due to related party | −26,533 | −4 | 205,128 | |
| Tax payable | — | −42,267 | −21,292 | |
| Net cash (used in) operating activities | −7 | −9 | −1 | |
| Deferred grant reimbursement | 19,699 | 37,235 | −22,455 | |
| Purchases of property and equipment | −169,917 | −396,451 | −288,712 | |
| Net cash (used in) investing activities | −150,218 | −359,216 | −311,167 | |
| Issuance of common shares | — | 15 | — | |
| Related Party Note | — | 4 | — | |
| Issuance of Warrants for Private placement | — | 11,819 | — | |
| Payments on finance lease obligations | −27,709 | — | — | |
| Net cash provided by (used in) financing activities | −27,709 | 19 | 1 | |
| NET INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS | −7 | 10 | −492,037 | |
| Interest Expense | 6,252 | — | — | |
| Income Taxes | — | — | 63,559 | |
| Conversion of SAFE Note to common shares | — | 1 | — | |
| Related party debt forgiveness | 147,103 | — | — | |
| Right-of-use assets obtained in exchange for new lease liabilities | 136,391 | — | — |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro
Frequently asked questions
What is EXOZYMES INC.'s CIK number?
EXOZYMES INC.'s SEC CIK number is 0002010788 (2010788). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find EXOZYMES INC.'s SEC filings?
All of EXOZYMES INC.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.